Showing results (71-80 of 494) with videos related to
Sort By:
Pageof 50
Health Policy (Amsterdam, Netherlands)|April 30, 2026
Deeming Doesn't Deliver: Reliance on foreign regulators targets the wrong stage of Canadian drug accessDaniel Eisenkraft Klein, Aaron S KesselheimJournal of Managed Care & Specialty Pharmacy|March 30, 2016
Drug Product Life-Cycle Management as Anticompetitive Behavior: The Case of MemantineVincent C Capati, Aaron S KesselheimPlos Medicine|March 16, 2016
An Uninformative Truth: The Logic of Amarin's Off-Label PromotionSpencer Phillips Hey, Aaron S KesselheimThe American Journal of Managed Care|August 30, 2021
CAAP rule and prescription drug pricesBryan S Walsh, Aaron S KesselheimPlos Medicine|May 9, 2018
The next forum for unraveling FDA off-label marketing rules: State and federal legislaturesMichael S Sinha, Aaron S KesselheimAmerican Journal of Therapeutics|March 11, 2010
Managing financial and nonfinancial conflicts of interest in healthcare deliveryAaron S Kesselheim, William H MaiselYale Journal of Health Policy, Law, and Ethics|September 4, 2015
Hatch-Waxman Turns 30: Do We Need a Re-Designed Approach for the Modern Era?Aaron S Kesselheim, Jonathan J DarrowHealth Affairs (Project Hope)|March 7, 2007
Confidentiality laws and secrecy in medical research: improving public access to data on drug safetyAaron S Kesselheim, Michelle M MelloHealth Affairs (Project Hope)|September 8, 2021
Controversy Over Using Quality-Adjusted Life-Years In Cost-Effectiveness Analyses: A Systematic Literature ReviewLeah Z Rand, Aaron S KesselheimThe Milbank Quarterly|August 28, 2025
Policy Options for Antimicrobial Resistance: Exploring Lessons From Environmental GovernanceIsaac Weldon, Kathleen Liddell, Kevin OuttersonPageof 50